Casdin Capital CTNM Position
Active6-Fund ConvergenceCasdin Capital held their position in Contineum Therapeutics, Inc. (CTNM) in Q4 2025, holding $1.7M worth of shares across 148,333 shares.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
CTNM is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for PIPE-791 Dose A in 776 days (May 31, 2028), making the timing of Casdin's position particularly relevant.
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Full company profile →Short Interest
8.7%
12.1 days to cover
Casdin Capital CTNM Position History
Frequently Asked Questions
Does Casdin Capital own CTNM?
Yes. As of Q4 2025, Casdin Capital holds 148,333 shares of Contineum Therapeutics, Inc. (CTNM) valued at $1.7M. This data comes from their SEC 13F filing.
How many hedge funds own CTNM?
6 specialist biotech hedge funds currently hold CTNM, including Perceptive Advisors, RA Capital Management, Baker Bros. Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy CTNM?
Casdin Capital's position in CTNM was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's CTNM position increasing or decreasing?
Casdin Capital held their CTNM position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CTNMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →